Open-Angle Glaucoma

The first patient in the Chinese portion of the Denali phase 3 clinical trial, investigating NCX 470 in patients with open-angle glaucoma or ocular hypertension, has been screened, according to a press release from Nicox.

The first patient has been enrolled in a trial investigating the stand-alone use of the Hydrus microstent in mild to moderate open-angle glaucoma, according to a press release from Ivantis.

The MINIject MIGS device has been approved in Europe for patients with open-angle glaucoma, according to a press release from iSTAR Medical.

Netarsudil 0.02% appears to be more effective at lowering IOP in patients with open-angle glaucoma or ocular hypertension than ripasudil 0.4% in a phase 3 clinical trial, according to a press release from Aerie Pharmaceuticals.

Netarsudil maintained IOP control and provided IOP-lowering efficacy when added to other treatments for patients with open-angle glaucoma or ocular hypertension, according to findings published in Current Medical Research and Opinion.

LAS VEGAS — The Omni surgical system reduced IOP through 3 months in patients with open-angle glaucoma, according to research presented at the American Society of Cataract and Refractive Surgery meeting.

Glaukos is moving forward with an FDA new drug application phase 3 clinical program for the iDose TR after finishing patient enrollment and randomization, according to a press release.

Glaukos and Santen have entered a new license agreement for the development and commercialization of the PreserFlo microshunt, replacing the previous agreements between the companies, according to a press release.

Roclanda has received marketing authorization from the Medicines and Healthcare Products Regulatory Agency in Great Britain, according to a press release from Aerie Pharmaceuticals.

Teva Pharmaceuticals USA has launched the first generic version of Azopt in the United States.